E-LIB Suche - Ergebnisse für: Lichtenstein, G

1

P954 Cumulative response to guselkumab through week 24 of i..:

Rubin, D ; Sands, B ; Lichtenstein, G...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1732-i1733 , 2024

Link: https://doi.org/10.1093/..

2

P1010 Guselkumab improves abdominal pain and bowel urgency ..:

Rubin, D ; Panés, J ; Feagan, B...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i1825-i1826 , 2024

Link: https://doi.org/10.1093/..

3

DOP49 Guselkumab improves health-related quality of life as..:

Panés, J ; Dignass, A ; Lichtenstein, G...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i161-i162 , 2024

Link: https://doi.org/10.1093/..

4

P814 Clinical trial design in Crohn's disease: interpreting..:

Khan, R M Q ; Schwartz, D A ; Sands, B E...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i948-i949 , 2023

Link: https://doi.org/10.1093/..

5

P493 QUASAR Induction Study 1 Cumulative Response to Guselk..:

Peyrin-Biroulet, L ; Rubin, D ; Lichtenstein, G...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i624-i625 , 2023

Link: https://doi.org/10.1093/..

6

P518 Safety of upadacitinib in ulcerative colitis: Long-ter..:

Panaccione, R ; Lichtenstein, G ; Nakase, H...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i644-i646 , 2023

Link: https://doi.org/10.1093/..

7

OP23 The efficacy and safety of guselkumab induction therap..:

Dignass, A ; Rubin, D ; Bressler, B...
Journal of Crohn's and Colitis. 16 (2022) Supplement_1 - p. i025-i026 , 2022

Link: https://doi.org/10.1093/..

8

DOP45 Long-term cardiac safety of ozanimod in phase 3 clini..:

Armuzzi, A ; Cross, R K ; Lichtenstein, G...
Journal of Crohn's and Colitis. 16 (2022) Supplement_1 - p. i094-i095 , 2022

Link: https://doi.org/10.1093/..

9

0628 On-Call Nights Lead to Executive Function Deficits in ..:

Appelbaum, M ; Givaty, G ; Lichtenstein, G..
Sleep. 41 (2018) suppl_1 - p. A233-A233 , 2018

Link: https://doi.org/10.1093/..

10

P511 Baseline characteristics of ulcerative colitis patient..:

Wolf, D. ; Lewis, J.D. ; Siegmund, B....
Journal of Crohn's and Colitis. 11 (2017) suppl_1 - p. S339-S340 , 2017

Link: https://doi.org/10.1093/..

11

P501 Baseline characteristics of Crohn's disease patients i..:

Siegel, C.A. ; Lichtenstein, G. ; Siegmund, B....
Journal of Crohn's and Colitis. 11 (2017) suppl_1 - p. S333-S334 , 2017

Link: https://doi.org/10.1093/..

12

P590 Reasons for discontinuation and switch of biologic the..:

Sebastian, S. ; Lewis, J.D. ; Siegmund, B....
Journal of Crohn's and Colitis. 11 (2017) suppl_1 - p. S381-S381 , 2017

Link: https://doi.org/10.1093/..

13

DOP076 A phase 2B, multicenter, randomized, placebo-control..:

Sands, B. ; Sandborn, W. ; Feagan, B.G....
Journal of Crohn's and Colitis. 11 (2017) suppl_1 - p. S71-S72 , 2017

Link: https://doi.org/10.1093/..

14

Clinical and demographic characteristics predictive of trea..:

Sandborn, W. J. ; Melmed, G. Y. ; McGovern, D. P. B....
Alimentary Pharmacology & Therapeutics. 42 (2015) 3 - p. 330-342 , 2015

Link: https://doi.org/10.1111/..

15

A post-hoc analysis:

Sandborn, W ; Rutgeerts, P ; Reinisch, W...
Inflammatory Bowel Diseases. 17 (2011) suppl_1 - p. S6-S6 , 2011

Link: https://doi.org/10.1093/..